HPCAIAC
8.4.2020 14:32:09 CEST | Business Wire | Press release
The HPC-AI Advisory Council (HPCAIAC) and the National Supercomputing Centre (NSCC) Singapore announced today that they have joined the global fight against COVID-19 by expanding the 2020 APAC HPC-AI competition to address education and applied learning towards accelerating bioscience research and discovery.
As part of the updated competition, student teams are now tasked to research, find and choose an HPC or AI application that can potentially be used as part of the global fight against COVID-19. Teams must demonstrate testing and benchmarking of the application, as well as explain how this application can best be accelerated. In addition, teams will also be required to focus on tuning and accelerating NAMD, a molecular dynamics code designed for high-performance simulation of large biomolecular systems. The NAMD application is being used at various supercomputing sites to run massive simulations of COVID-19 to aid researchers design new drugs and vaccines to combat the virus.
The APAC HPC-AI competition promotes the latest HPC and AI technologies to the universities and research centers and trains the students with the latest HPC and AI technologies to help bridge the gap between universities/research institutes and industries. The competition also trains the undergraduate and graduate students to practice on the newest HPC and AI platforms, and provides the key ingredients and industry tools to optimize the production applications. Open for registration until May 17, the 3rd Annual 2020 APAC HPC-AI competition expects to host multiple teams from across the APAC region.
“While not ignoring commercial and scientific applications, it has become importantly clear that we must put further emphasis on tuning and optimizing applications in the medical and bioscience field. By expanding the competition’s charter to address applications specifically used for groundbreaking COVID-19 simulations, the HPC-AI Advisory Council and NSCC are taking the action to educate and train the next generation of HPC scientists and programmers that may aid the world in viral outbreaks or pandemics in the future,” said Gilad Shainer, Chairman of the HPC-AI Advisory Council.
"Computer models of viruses and viral protein structures, especially for high resolution analysis, is very computationally intensive. Molecular docking experiments in silico, to screen for potentially effective drugs that block viral functions, and molecular-modeling applications, such as GROMACS and NAMD, must be optimized and benchmarked for simulations to run as efficiently as possible. By training our young aspiring programmers using real-world scenarios such as COVID-19, we can better prepare them to provide solutions to future global issues from pandemics to climate change. More than that, we hope that this will give our youth a better appreciation for the significant role that HPC and AI can play, and how they can use the skills learned in this competition to contribute more meaningfully to society," said Professor Tan Tin Wee, Chief Executive, National Supercomputing Centre (NSCC) Singapore.
Co-organized by the HPC-AI Advisory Council and NSCC, the competition is sponsored by Mellanox, NVIDIA, AMD and WekaIO with additional support from the Singapore Advanced Research and Education Network (SingAREN).
For more information on the 3rd APAC HPC-AI competition and to register teams, please visit the HPC-AI Advisory Council website at http://hpcadvisorycouncil.com/events/2020/APAC-AI-HPC/
About HPC-AI Advisory Council
Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to bridge the gap between high-performance computing and artificial intelligence use and its potential, bringing the beneficial capabilities of HPC and AI to new users for better research, education, innovation and product manufacturing, and brings users the expertise needed to operate HPC and AI systems, provide application designers with the tools needed to enable parallel computing, and to strengthen the qualification and integration of HPC and AI system products. For more information, please visit: www.hpcadvisorycouncil.com .
About National Supercomputing Centre Singapore
The National Supercomputing Centre (NSCC) Singapore was established in 2015 and manages Singapore’s first national petascale facility with available high performance computing (HPC) resources. As a National Research Infrastructure we support the HPC research needs of the public and private sectors, including research institutes, institutes of higher learning, government agencies and companies. With the support of its stakeholders, including Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), National University of Singapore (NUS), Singapore University of Technology and Design (SUTD), National Environment Agency (NEA) and Technology Centre for Offshore and Marine, Singapore (TCOMS), and funded by the National Research Foundation (NRF), NSCC catalyses national research and development initiatives, attracts industrial research collaborations and enhances Singapore’s research capabilities. For more information, please visit https://www.nscc.sg/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
